Targeted Cancer Therapy Reshapes Tumor Peptide Landscape Visible to Immune System | Research

The takeaway

Molecularly targeted therapies alter the immunopeptidome (MHC-presented peptides) of DLBCL, revealing new tumor-specific peptides that could be targeted by combination immunotherapy.

Treatment reveals new targets
Targeted therapy changes which peptides cancer cells display to the immune system — potentially enabling immune attack through combination therapy

What the researchers found

Molecularly targeted therapy reshapes DLBCL immunopeptidome, revealing novel tumor-specific MHC-presented peptides that could serve as targets for combination immunotherapy.

Why it matters

If targeted therapy reveals new immune targets on cancer cells, it provides the scientific basis for powerful drug-immunotherapy combinations.

How the study worked

Immunopeptidomics analysis of DLBCL cells before and after molecularly targeted therapy, identifying changes in MHC-presented peptide repertoire.

What this study cannot tell us

In vitro. Limited to DLBCL. Whether exposed peptides generate meaningful immune responses in vivo unknown.

How to read the evidence

Immunopeptidomics discovery study.

When this study was published

Published in 2025.

The bigger picture

Targeted therapy may inadvertently make cancers more visible to the immune system — turning a pharmacological treatment into an immunological opportunity.

Questions still open

Could drug-induced immunopeptidome changes guide personalized cancer vaccine design?
Would checkpoint inhibitors combined with targeted therapy exploit these newly exposed peptides?
Is immunopeptidome reshaping a general phenomenon across cancer types?

Common questions

How does targeted therapy help the immune system?

Cancer drugs change which protein fragments cancer cells display on their surface. This can reveal new targets that the immune system can recognize and attack — making combination therapy more effective.

Could this lead to better cancer treatment?

Yes. If targeted therapy makes new tumor peptides visible, adding immunotherapy could attack these newly revealed targets. This provides the scientific basis for combining drug types.

Read the original research

Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).

Neoplasia (New York, N.Y.), 73, 101278

View on PubMed ↗Publisher’s paper ↗

Citation

Khairkhah, Niloofar; Owolabi, Habeebah; Namvar, Ali; Ibrahim, Mostafa M H; Nyayapathy, Seeta; Jones, Richard; Rumble, Julie M; Whitehead, Christopher E; Sebolt-Leopold, Judith S; Everest-Dass, Arun; Galban, Stefanie. (2026). Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).. Neoplasia (New York, N.Y.), 73, 101278. https://doi.org/10.1016/j.neo.2026.101278